Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer

Company Overview - Sutro Biopharma, Inc. is a clinical-stage oncology company focused on the discovery and development of precisely designed cancer therapeutics, utilizing its proprietary cell-free technology, XpressCF® [3][4] - The company is advancing its lead candidate, luveltamab tazevibulin (luvelta), which is a registrational-stage antibody-drug conjugate (ADC) targeting folate receptor alpha (FolRα) in clinical studies [3][4] Leadership Appointment - Dr. Barbara Leyman has been appointed as Chief Business Development Officer, effective July 8, 2024, bringing 20 years of experience in life sciences business development and corporate strategy [4][5] - Dr. Leyman previously held senior positions at GenEdit, Lyell Immunopharma, and Calico Life Sciences, and has a strong background in venture capital and biotechnology [5] Compensation and Inducement Grants - In connection with Dr. Leyman's appointment, the Compensation Committee granted her options to purchase 125,000 shares of Sutro common stock and 100,000 restricted stock units (RSUs) [10] - The RSUs will vest over four years, with one-fourth vesting on the one-year anniversary of her hire date, and the stock options will have a term of ten years [6][10] Strategic Vision - Dr. Leyman expressed excitement about joining Sutro and highlighted the company's unique approach to developing ADCs and other therapies that can significantly improve patient care [9] - The company aims to leverage its innovative technology to expand the potential of its medicines and continue building value with luvelta [9]